ProQR Therapeutics N.V. logo
ProQR Therapeutics N.V. PRQR
$ 2.07 0.24%
report update icon

Quarterly report 2025-Q4
added 05-12-2026

ProQR Therapeutics N.V. Financial Statements 2025-2011 | PRQR

Annual Financial Statements ProQR Therapeutics N.V.

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

162 M 121 M 193 M 111 M 68.7 M 188 M 291 M 454 M 85 M 96.9 M 123 M 223 M - - -

Shares

105 M 86.1 M 81 M 71.6 M 64.2 M 41 M 41 M 34.1 M 25.4 M 23.3 M 23.3 M 11.1 M - - -

Historical Prices

1.54 1.4 2.38 1.55 1.07 4.57 7.09 13.3 3.35 4.05 4.34 18.8 - - -

Net Income

-42.2 M -27.8 M -27.7 M -64.2 M -61.7 M -46.6 M -56.5 M -36.9 M -43.6 M -39.1 M -20.8 M -12.1 M -3.25 M - -

Gross Profit

- - - - - - - - - - - 313 K - - -

Operating Income

-43.4 M -30.5 M -31.9 M -65.2 M -57.2 M -42.4 M -57.4 M -36.3 M -40.5 M -39.6 M -27 M - - - -

Interest Expense

929 K 1.08 M 1.2 M - 3.4 M 2.04 M - - - - - - - - -

EBITDA

-43.4 M -30.5 M -31.9 M -65.2 M -57.2 M -42.4 M -57.4 M -36.3 M -40.5 M -38.5 M -26.6 M -16.3 M -3.19 M - -

Operating Expenses

59.8 M 50 M 41.4 M 69.5 M 59.6 M 51.8 M 59.4 M 42.1 M 42 M 39.8 M 27 M 16.5 M - - -

General and Administrative Expenses

15.1 M 13.7 M 16.2 M 18.7 M 17.4 M 13.7 M 12.9 M 12.5 M 10.8 M 9.48 M 6.84 M 6.51 M 786 K - -

All numbers in EUR currency

Quarterly Income Statement ProQR Therapeutics N.V.

2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

105 M 105 M 105 M 105 M 86.1 M 81.7 M 81.7 M 81.6 M 81 M 81 M 80.9 M 80.9 M - - - 71.4 M 71.2 M 68.3 M 66.1 M 50.8 M 50.2 M 50.1 M 50 M 49.9 M 47.4 M 38.9 M 38.9 M 38.9 M - 33.4 M 31.9 M - - - 24 M - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

-42.2 M -11 M -12.2 M -10.1 M -27.8 M -8.11 M -2.69 M -7.66 M -27.7 M -5.42 M -7.98 M -8.86 M - - - -14.4 M -18.2 M -15.1 M -15.8 M -12.6 M -13.2 M -13.2 M -4.12 M -16.1 M -18.6 M -12.2 M -11.7 M -14.2 M - -5.99 M -7.4 M - - - -11.4 M - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

- - - - - 3.84 M 6.3 M 4.45 M - 1.37 M 1.2 M 655 K - - - 1.23 M 239 K 872 K 243 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-43.4 M -11.3 M -12.2 M -10.8 M -30.5 M -8.72 M -3.6 M -8.08 M -31.9 M -7.39 M -8.81 M -9.39 M - - - -16.9 M -17.3 M -14.6 M -13.2 M -12.1 M -11.7 M -10.9 M -3.36 M -16.5 M -17.4 M -13.4 M -11.8 M -14.7 M - -5.92 M -7.67 M - - - -10.2 M - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

929 K - - - 1.08 M - - - 1.2 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

-43.4 M -11.3 M -12.2 M -10.8 M -30.5 M -8.72 M -3.6 M -8.08 M -31.9 M -7.39 M -8.81 M -9.39 M - - - -16.9 M -17.3 M -14.6 M -13.2 M -12.1 M -11.7 M -10.9 M -3.36 M -16.5 M -17.4 M -13.4 M -11.8 M -14.7 M - -5.92 M -7.67 M - - - -10.2 M - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

59.8 M 14.2 M 16.2 M 15.6 M 50 M 12.7 M 10.1 M 12.7 M 41.4 M 8.76 M 10.1 M 10.1 M - - - 18.3 M 17.8 M 15.7 M 13.9 M 12.2 M 11.9 M 11.1 M 12 M 16.7 M 17.8 M 14 M 12.4 M 15.2 M - 8.88 M 8.64 M - - - 10.4 M - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

15.1 M 3.12 M 4.82 M 3.23 M 13.7 M 3.28 M 3.01 M 3.45 M 16.2 M 3.32 M 4.14 M 4.03 M - - - 4.91 M 5.32 M 4.59 M 4.12 M 3.34 M 3.51 M 2.81 M 3.45 M 3.92 M 3.92 M 2.9 M 2.88 M 3.19 M - 2.58 M 2.65 M - - - 2.89 M - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in EUR currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements ProQR Therapeutics N.V. PRQR
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting ProQR Therapeutics N.V. plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Фармсинтез Фармсинтез
LIFE
- - - russiaRussia
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Завод ДИОД Завод ДИОД
DIOD
- - - russiaRussia
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Cleveland BioLabs, Inc. Cleveland BioLabs, Inc.
CBLI
- -7.31 % $ 49 M usaUSA
Five Prime Therapeutics, Inc. Five Prime Therapeutics, Inc.
FPRX
- - $ 1.77 B usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
- -6.81 % $ 3.04 B usaUSA
Biofrontera AG Biofrontera AG
BFRA
- -8.24 % $ 105 M germanyGermany
Catabasis Pharmaceuticals, Inc. Catabasis Pharmaceuticals, Inc.
CATB
- -6.97 % $ 657 M usaUSA
China Biologic Products Holdings, Inc. China Biologic Products Holdings, Inc.
CBPO
- 1.68 % $ 4.65 B chinaChina
Flexion Therapeutics, Inc. Flexion Therapeutics, Inc.
FLXN
- - $ 459 M usaUSA
Heat Biologics, Inc. Heat Biologics, Inc.
HTBX
- -5.76 % $ 99.8 M usaUSA
Kindred Biosciences, Inc. Kindred Biosciences, Inc.
KIN
- 0.11 % $ 419 M usaUSA
Shineco, Inc. Shineco, Inc.
TYHT
- -3.90 % $ 97.2 M chinaChina
Millendo Therapeutics, Inc. Millendo Therapeutics, Inc.
MLND
- -5.36 % $ 20.2 M usaUSA
Intec Pharma Ltd Intec Pharma Ltd
NTEC
- -12.45 % $ 17.7 M israelIsrael
Progenity, Inc. Progenity, Inc.
PROG
- -3.47 % $ 164 M usaUSA
CTI BioPharma Corp. CTI BioPharma Corp.
CTIC
- - $ 1.2 B usaUSA
Strongbridge Biopharma plc Strongbridge Biopharma plc
SBBP
- 1.52 % $ 136 M usaUSA
Decibel Therapeutics Decibel Therapeutics
DBTX
- - $ 123 M usaUSA
Seneca Biopharma, Inc. Seneca Biopharma, Inc.
SNCA
- -1.19 % $ 28.7 M usaUSA
IVERIC bio IVERIC bio
ISEE
- - $ 5.51 B usaUSA
Myovant Sciences Ltd. Myovant Sciences Ltd.
MYOV
- -0.04 % $ 2.62 B usaUSA
Trean Insurance Group Trean Insurance Group
TIG
- - $ 316 M usaUSA
Virpax Pharmaceuticals Virpax Pharmaceuticals
VRPX
- -45.12 % $ 2.85 M usaUSA
Metacrine Metacrine
MTCR
- - $ 24.2 M usaUSA
Celsion Corporation Celsion Corporation
CLSN
- -6.63 % $ 13.9 M usaUSA
Генетико Генетико
GECO
- - - russiaRussia
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
AnaptysBio AnaptysBio
ANAB
$ 56.8 0.94 % $ 1.63 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
BiondVax Pharmaceuticals Ltd. BiondVax Pharmaceuticals Ltd.
BVXV
- 0.74 % $ 768 M israelIsrael
Abcam plc Abcam plc
ABCM
- - $ 4.9 B britainBritain
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Affimed N.V. Affimed N.V.
AFMD
- -34.95 % $ 21.5 M germanyGermany
ОЗОН Фармацевтика ОЗОН Фармацевтика
OZPH
- - - russiaRussia
AnPac Bio-Medical Science Co., Ltd. AnPac Bio-Medical Science Co., Ltd.
ANPC
- -1.58 % $ 28.1 M chinaChina
Celyad Oncology SA Celyad Oncology SA
CYAD
- - $ 12.5 M belgiumBelgium
Gracell Biotechnologies Gracell Biotechnologies
GRCL
- - $ 3.37 B chinaChina
Galapagos NV Galapagos NV
GLPG
- - $ 1.83 B belgiumBelgium
Teligent, Inc. Teligent, Inc.
TLGT
- -13.85 % $ 16.1 M usaUSA
Viela Bio, Inc. Viela Bio, Inc.
VIE
- - $ 2.91 B usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Aphria Inc. Aphria Inc.
APHA
- -0.45 % $ 4.87 B canadaCanada
Aerpio Pharmaceuticals, Inc. Aerpio Pharmaceuticals, Inc.
ARPO
- -0.90 % $ 104 M usaUSA